Regeneron (REGN) Tops Q4 EPS by 70c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
February 8, 2018 6:30 AM ESTTARRYTOWN, N.Y., Feb. 8, 2018 /PRNewswire/ --
Fourth quarter 2017 GAAP net income per diluted share decreased by 32% to $1.50 versus fourth quarter 2016, and includes a charge of $2.82 per diluted share in connection with enactment of U.S. tax reform legislation Fourth quarter 2017 non-GAAP net income per diluted share increased 72% to $5.23 versus fourth quarter 2016 Fourth quarter 2017 EYLEA® (aflibercept) Injection U.S. net sales increased 14% to $975 million versus fourth quarter 2016 and full year 2017 EYLEA U.S. net sales increased 11% to $3.70 billion versus full year 2016 Fourth quarter 2017 EYLEA global net... More